The purpose of this research study is to measure the tolerability and preliminary efficacy of a drug, galantamine, to treat metabolic syndrome (MetS) by reducing circulating inflammation in people with spinal cord injury (SCI). Galantamine is FDA-approved for the treatment of Alzheimer's disease. Here, the drug is considered experimental for the purposes of this study.
Adults aged 21-75 years (male or female)
Chronic (≥1 year post injury) traumatic non-progressive spinal cord injury (SCI)
Wheelchair user for community mobility
Injury level of tetraplegia (cervical level) or paraplegia (all levels)
Diagnosis of neurological injury or condition other than SCI
Progressive condition that would be expected to change neurological status
Signs and symptoms of cardiovascular disease or cardiac arrhythmias
Resting heart rate <45 bpm
Northwell Health
Lead sponsor
Bronx Veterans Medical Research Foundation, Inc
Collaborator
Kessler Institute for Rehabilitation
Collaborator